Blair William & Co. IL Sells 4,804 Shares of Johnson & Johnson $JNJ

Blair William & Co. IL lowered its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 952,857 shares of the company's stock after selling 4,804 shares during the quarter. Blair William & Co. IL's holdings in Johnson & Johnson were worth $145,549,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of JNJ. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 0.5% during the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock worth $38,800,371,000 after purchasing an additional 1,170,120 shares during the last quarter. Northern Trust Corp raised its position in Johnson & Johnson by 0.4% in the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock worth $5,131,723,000 after acquiring an additional 130,645 shares during the period. Bank of New York Mellon Corp raised its position in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 3.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock worth $3,133,602,000 after acquiring an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in Johnson & Johnson by 2.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock worth $3,031,955,000 after acquiring an additional 448,666 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on JNJ. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a research note on Monday, October 6th. Barclays increased their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Royal Bank Of Canada reiterated an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a research note on Friday. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a research note on Friday, October 3rd. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $192.94.

Johnson & Johnson Price Performance

JNJ stock opened at $190.66 on Friday. The firm has a 50 day moving average of $178.48 and a 200-day moving average of $163.77. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10. The firm has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.